About Amyotrophic Lateral Sclerosis Assn
To lead the fight to treat and cure ALS through research, patient care and support, and advocacy.
Focus Areas
ALS researchDrug development / translational researchClinical fellowships and seed grantsPatient care and support servicesAdvocacy and policy
Who They Fund
clinical researchers and investigators (including postdoctoral fellows)research institutions and centers (centers of excellence, trial sites)clinical trial infrastructure / trial sitespatients implicitly served by trials and quality-of-care programs (disease-affected populations)industry or contract partners involved in drug development
About Amyotrophic Lateral Sclerosis Assn
Amyotrophic Lateral Sclerosis Assn directs large-scale funding toward ALS research, patient care, support services, and advocacy, with a strong emphasis on moving work into clinical use. In the recent grants list, that shows up in a $750,000 clinical trial award to Projenx Inc and a $600,000 trial-capacity and clinical trial award to University of Kansas Medical Center Research Institute Inc. The pattern is not limited to trials: the organization also funded drug-development contracts, prevention work, quality-of-care projects, and fellowships, reflecting a program mix that reaches from early-stage science to care delivery. Its largest awards in the data include multi-hundred-thousand-dollar commitments to universities, hospitals, research institutes, and biotech companies. The grants also point to a portfolio that includes strategic initiatives and partnership programs alongside project-specific research awards. Recipients range from academic medical centers such as University of Massachusetts Medical School and Massachusetts General Hospital - Research to industry groups such as Aquilus Pharmaceuticals Inc and Libra Therapeutics, showing that the funder backs both institutional research infrastructure and translational development. This is a public charity with national reach and a research-forward funding model built around ALS-specific projects.
What Amyotrophic Lateral Sclerosis Assn Funds
The clearest theme is translational and clinical ALS research. The foundation gave $500,000 to Aquilus Pharmaceuticals Inc for a clinical trial award and $300,000 to Libra Therapeutics for a drug development contract, both aimed at advancing therapies toward patient use. It also supported Myrobalan Therapeutics Inc with a $250,000 drug development contract. A second strand is prevention and early intervention. Regents of the University of Michigan received $349,864 tied in part to a prevention program, while The Trustees of Columbia University in the City of New York received $349,286 with prevention-program support and other research components. The third area is quality and care delivery. Mayo Clinic Arizona received a $400,000 award that included quality-of-care programming, and The Regents of the University of California San Francisco received $250,000 for a quality-of-care program. These awards sit alongside trial-capacity support, showing that the foundation funds both therapeutic development and the systems needed to deliver ALS care and research.
Financial Snapshot
Annual Giving
$3.5M
Total Assets
$100.4M
Total Revenue
$20.9M
Total Expenses
$26M
Typical Grant Size
Most grants fall between $25K and $75K, with a median of $38K.
25th Percentile
$25K
Median
$38K
75th Percentile
$75K
Geographic Reach
National41 states funded
About 1% of grants go to recipients in CA.
Funding intensity
LowHigh
Headquarters
Unlock Deep Analysis
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeSee Similar Funders
Free Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeExplore related grant guides
Want a Personalized Pitch for Amyotrophic Lateral Sclerosis Assn?
Sign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Free plan available
No contracts
Cancel anytime